Latham & Watkins Advises on Immunome’s US$200 Million Public Offering of Common Stock

Immunome, Inc. (Immunome) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, has announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of US$20.00 per share. All of the shares are to be sold by Immunome. The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be US$200.00 million. In addition, Immunome has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on February 16, 2024, subject to the satisfaction of customary closing conditions.

Latham & Watkins LLP is advising the underwriters in the offering, with a capital markets team led by San Diego partner Matt Bush, with associates Julian Brody, Peter Simon, Shelby Harrison, and Sterling Swift. Advice was also provided on regulatory matters by Washington, D.C. counsel Chad Jennings and Bay Area partner Betty Pang; and on IP matters by San Diego associate Robert Yeh.